Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filingsEarnings calendarWatchlist
MORE TOOLS
Gold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

CongressSearchHomeWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View SNOA insider activity ↗

SNOASonoma Pharmaceuticals, Inc.

THE LATEST REPORTED YEAR

The company reported a loss.

$3.18M net loss for the year ended March 31, 2026. These are reported results, not a forecast or a stock recommendation.

Revenue$19.53MYear ended March 31, 2026
Profit or loss-$3.18MYear ended March 31, 2026
Cash from the business-$3.93MYear ended March 31, 2026
Total assets$18.11MAs of June 30, 2026
Total liabilities$11.51MAs of June 30, 2026
Cash & equivalents$5.34MAs of June 30, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$18.97M
2019-03
$17.93M
2020-03
$18.63M
2021-03
$12.63M
2022-03
$13.27M
2023-03
$12.74M
2024-03
$14.29M
2025-03
$19.53M
2026-03

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
April 1, 2025 – March 31, 2026$19,529,000June 16, 202610-K ↗
April 1, 2024 – March 31, 2025$14,288,000June 16, 202610-K ↗
April 1, 2023 – March 31, 2024$12,735,000June 17, 202510-K ↗
April 1, 2022 – March 31, 2023$13,272,000June 17, 202410-K ↗
April 1, 2021 – March 31, 2022$12,628,000June 21, 202310-K ↗
April 1, 2020 – March 31, 2021$18,629,000July 13, 202210-K ↗
April 1, 2019 – March 31, 2020$17,928,000July 14, 202110-K ↗
April 1, 2018 – March 31, 2019$18,970,000July 10, 202010-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · Retrieved October 15, 2026

Response SHA-256: ba342c58a8f605b240c695aa547c24b5a5b61a01177b72c6b7513a9947efc3b8

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.